Comparative Pharmacology
Head-to-head clinical analysis: NEO CORTEF versus NEO MEDROL ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORTEF versus NEO MEDROL ACETATE.
NEO-CORTEF vs NEO-MEDROL ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Methylprednisolone acetate is a corticosteroid with glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression, suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes), and inhibition of immune cell proliferation and function.
Apply a thin layer to the affected area 3 to 4 times daily. Use the 0.5% strength for mild conditions and 1% for more severe conditions.
Intra-articular, intrabursal, or periarticular injection: 4-40 mg depending on joint size. For intralesional injection: 10-40 mg per lesion. For systemic use (intramuscular): 40-120 mg every 1-5 weeks as needed.
None Documented
None Documented
Terminal half-life 2-4 hours for neomycin; hydrocortisone half-life 1-2 hours. Clinical context: q6-8h dosing.
Terminal half-life approximately 24-36 hours; prolonged in hepatic impairment; sufficient for once-daily dosing.
Renal (70-80% as free drug and metabolites), fecal (20-30% via bile).
Primarily renal: ~75-90% as metabolites and <5% unchanged. Biliary/fecal: ~10-25%.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic